Njira Zochizira Khansa Yam'mapapo Yam'mapapo 2026: Kupambana Kwatsopano kwa ADC & Immunotherapy 

Njira zazing'ono zothandizira khansa ya m'mapapo mu 2026 asintha kwambiri, akusintha kuchoka pamankhwala a chemotherapy okha kupita ku kuphatikiza kopitilira muyeso komwe kumaphatikizapo immunotherapy, antibody-drug conjugates (ADCs), ndi omwe amatsata T-cell. Miyezo yamakono ikuphatikiza mankhwala a chemotherapy opangidwa ndi platinamu ophatikizidwa ndi PD-L1 inhibitors kuti asamalire mzere woyamba, pomwe zotsogola zatsopano monga ma DLL3 omwe akuwongolera komanso ma ADC amtundu wapawiri akumasuliranso zotsatira za kupulumuka kwa matenda ocheperako komanso ochulukirapo.

Kumvetsetsa Maonekedwe Amakono a Njira Zochizira Khansa Yam'mapapo Yamaselo Ang'onoang'ono

Khansara yaing'ono ya m'mapapo ya m'mapapo (SCLC) imakhalabe imodzi mwamatenda oopsa kwambiri, omwe amadziwika ndi kukula msanga komanso kuyambika kwa metastasis. Zakale, njira zazing'ono zothandizira khansa ya m'mapapo Zinali zochepa ku platinum-etoposide chemotherapy, yomwe inkapereka ziwopsezo zoyamba zoyankhira koma kusapulumuka kwanthawi yayitali. Kupulumuka kwapakatikati kwa SCLC (ES-SCLC) sikunadutse chaka chimodzi.

Komabe, mawonekedwe achirengedwe asintha. Kuphatikizika kwa ma immune checkpoint inhibitors mu ma protocol a mzere woyamba kwakhala mulingo watsopano wapadziko lonse lapansi. Kuphatikiza apo, 2026 ndi chaka chofunikira kwambiri pomwe njira zatsopano, kuphatikiza ma T-cell ma bispecific T-cell ndi ma ADC am'badwo wotsatira, zikuyenda kuchokera ku magawo oyesera kupita ku zenizeni zachipatala. Kupititsa patsogolo kumeneku kumayang'ana kufunikira kofunikira kwa njira zochiritsira za mzere wachiwiri ndi wachitatu, dera lomwe lakhala likukhazikika kwazaka zambiri.

Kugawika kwa SCLC mu Limited-Stage (LS-SCLC) ndi Extensive-Stage (ES-SCLC) ikupitiriza kulamula njira yoyamba yothandizira. LS-SCLC imatha kuchiritsidwa ndi chemoradiotherapy yotsatiridwa ndi consolidation immunotherapy. Mosiyana ndi izi, ES-SCLC imayang'aniridwa ngati matenda osachiritsika, kuyang'ana pakutalikitsa kupulumuka ndikukhalabe ndi moyo wabwino kudzera mu njira zamankhwala. Kumvetsetsa kusiyanitsa kumeneku ndikofunikira kwa odwala ndi osamalira omwe akuyenda movutikira njira zazing'ono zothandizira khansa ya m'mapapo.

Udindo wa Mamolekyulu a Subtyping mu Chithandizo Chamakono

Kafukufuku waposachedwa wawonetsa kusiyanasiyana kwa SCLC, zomwe zimatsogolera kuzindikirika kwa ma molecular subtypes potengera mafotokozedwe azinthu zazikulu zolembera monga ASCL1, NEUROD1, POU2F3, ndi YAP1. Kusanja uku sikulinso kwamaphunziro; ikuyamba kukhudza mapangidwe a mayeso azachipatala ndi njira zochiritsira zaumwini. Mwachitsanzo, ma subtypes ena amatha kuyankha bwino kwa ma immunotherapies kapena othandizira omwe akutsata monga DLL3 inhibitors.

Ngakhale kuwunika kwapadziko lonse kwa ma subtypes awa sikunachitikebe m'zipatala zonse, kuzindikira za mitundu yosiyanasiyana ya zamoyo kumathandizira kufotokoza chifukwa chake odwala ena amayankha bwino kwambiri ku immunotherapy pomwe ena samatero. Pamene tikudutsa mu 2026, chiyembekezero ndichakuti mbiri ya mamolekyu idzakhala gawo lodziwika bwino la kayendetsedwe kake, ndikuyeretsanso kusankhidwa kwa ma cell. njira zazing'ono zothandizira khansa ya m'mapapo.

Miyezo Yoyamba: Kuphatikiza kwa Immunotherapy

Mwala wapangodya wamankhwala amakono oyamba a khansa yaing'ono ya m'mapapo yam'mapapo ndi kuphatikiza kwa chemotherapy yochokera ku platinamu ndi chitetezo chamthupi. Njirayi yawonetsa kupindula kosasinthika kupulumuka pa mayesero angapo akuluakulu a Phase III, kukhazikitsa chizindikiro chatsopano cha chisamaliro.

Njirayi imaphatikizapo kugwiritsa ntchito mankhwala a chemotherapy kuti apangitse kufa kwa maselo a immunogenic, "kuyambitsa" chotupacho. The immunotherapy yowonjezera, yomwe nthawi zambiri imakhala PD-L1 kapena PD-1 inhibitor, imalepheretsa kutsekedwa kwa ma T-cell, kulola kuti chitetezo cha mthupi chitetezeke ku maselo a khansa. Synergy iyi yasintha momwe odwala ambiri amakhalira.

• Atezolizumab: Kutengera ndi mayeso a IMpower133, atezolizumab kuphatikiza carboplatin ndi etoposide inali regimen yoyamba kuwonetsa phindu lalikulu la kupulumuka. Zambiri zotsatiridwa kwanthawi yayitali zomwe zidaperekedwa mu 2026 zimatsimikizira kupulumuka kokhazikika, ndi kagulu kakang'ono ka odwala omwe apulumuka kupitilira zaka zisanu.
• Durvalumab: Mlandu wa CASPIAN unakhazikitsa durvalumab kuphatikiza platinamu-etoposide ngati njira ina yolimba. Zosintha zaposachedwa zikuwonetsa mbiri yake yabwino yachitetezo komanso kusinthasintha pakukonza, ndikupangitsa kukhala chisankho chokondedwa m'machitidwe ambiri azaumoyo.
• Serplulimab: Zomwe zikubwera zikuwonetsa kuti serplulimab, buku la PD-1 inhibitor, imapereka mphamvu. Kafukufuku woperekedwa pamisonkhano yayikulu ya oncology mu 2026 akuwonetsa zotsatira zabwino zikagwiritsidwa ntchito limodzi ndi chemotherapy, makamaka pazambiri za odwala.
• Adebrelimab: Kupanga kwapakhomo kumeneku kwawonetsa zotsatira zochititsa chidwi m'maphunziro akuluakulu. Zosintha zazitali za kafukufuku wa CAPSTONE-1 zikuwonetsa kusintha kwakukulu pakupulumuka kwapakatikati, kulimbikitsa kufunikira kwa othandizira osiyanasiyana a immunotherapy pagulu lankhondo.

Consolidation Therapy for Limited-Stage Disease

Kwa odwala omwe ali ndi matenda ocheperako, cholinga chamankhwala ndichochiza. Muyezo wa chisamaliro umaphatikizapo chemotherapy therapy (cCRT). Kupambana kwakukulu m'zaka zaposachedwa ndikukhazikitsidwa kwa consolidation immunotherapy kutsatira cCRT.

Kuyesa kwa ADRIATIC kwasintha kwambiri pamasewerawa. Zinawonetsa kuti kuperekera durvalumab ngati chithandizo chophatikizira pambuyo pa cCRT yopambana kumakulitsa kupulumuka kopanda kupitilira komanso kupulumuka kwathunthu. Kupeza uku kwadzetsa kuvomerezedwa kwamalamulo ndi zosintha zamalangizo, zomwe zimapangitsa kuphatikiza immunotherapy kukhala kofunikira kwa odwala oyenerera a LS-SCLC.

Kuphatikiza apo, kufufuza kwa madongosolo a hypofractionated radiotherapy kuphatikiza ndi immunotherapy kukupitilira. Zotsatira zoyamba zikuwonetsa kuti kusintha kwa ma radiation kumathandizira kuyankha kwa chitetezo chamthupi, zomwe zitha kupititsa patsogolo zotsatira zake. Njira zosinthira izi zikuyimira m'mphepete mwa njira zazing'ono zothandizira khansa ya m'mapapo kwa matenda am'deralo.

Kuwonjezeka kwa Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates (ADCs) amaimira gulu losintha njira zazing'ono zothandizira khansa ya m'mapapo. Mosiyana ndi chemotherapy yachikhalidwe, yomwe imakhudza maselo onse omwe amagawikana mwachangu, ma ADC amakhala ngati "mivi yowongoleredwa." Amakhala ndi antibody yomwe imayang'ana puloteni inayake pa cell ya khansa, yolumikizidwa ndi kuchuluka kwamphamvu kwa cytotoxic. Ma antibody akamangirira chandamale, zovutazo zimalowetsedwa mkati, ndipo zolipira zimatulutsidwa mwachindunji mkati mwa cell chotupa, ndikuchepetsa kuwonongeka kwa minofu yathanzi.

Mu 2026, ma ADC akupeza mphamvu osati ngati njira zachiwiri zochiritsira komanso kuphatikiza ndi immunotherapy pamankhwala oyamba. Njira yapawiriyi imathandizira kulondola kwa ADC komanso mphamvu yadongosolo yachitetezo cham'thupi.

B7-H3 Ma ADC Olunjika: Ifinatamab Deruxtecan

Chimodzi mwazosangalatsa kwambiri ndikutuluka kwa ma ADC omwe akutsata B7-H3, monga ifinatamab deruxtecan (I-DXd). B7-H3 ndi puloteni yomwe imawonetsedwa kwambiri pama cell a SCLC koma imakhala yochepa m'magulu abwinobwino, ndikupangitsa kuti ikhale chandamale.

Zomwe zafotokozedwa posachedwa zikuwonetsa lonjezo lodabwitsa. Odwala omwe ali ndi siteji yayikulu ya SCLC omwe adapita patsogolo pambuyo pa chithandizo cham'mbuyomu, I-DXd idawonetsa chiwopsezo choyankhira choposa 50% komanso chiwopsezo cha matenda opitilira 90%. Mwina motsutsa kwambiri, wothandizira uyu wawonetsa kuthekera kodutsa chotchinga chamagazi muubongo.

Ma metastases muubongo ndizovuta komanso zowononga za SCLC. Mankhwala ochiritsira achikhalidwe nthawi zambiri amalephera kulowa mkatikati mwa minyewa mogwira mtima. Kutha kwa I-DXd kuchepetsa zotupa zam'mimba kumapereka mwayi kwa odwala omwe kale anali ndi zosankha zochepa. Mayesero omwe akupitirirabe a Gawo lachitatu akufanizira wothandizira uyu ndi mankhwala amphamvu amphamvu, ndipo zotsatira zake zikuyembekezeka kutanthauziranso mulingo wachiwiri wa chisamaliro.

Ma ADC Olunjika Pawiri: Iza-bren (BL-B01D1)

Malire ena ndikukula kwa ma ADC a bispecific. Iza-bren (BL-B01D1) ndi gulu loyamba la EGFR×HER3 lolunjika pawiri la ADC. Ngakhale kuti EGFR ndi HER3 nthawi zambiri zimagwirizanitsidwa ndi khansa ya m'mapapo yopanda maselo ang'onoang'ono, mawu awo mu SCLC ndi makina apadera a mankhwalawa apereka zotsatira zodabwitsa.

Kafukufuku waposachedwa wa Phase II kuphatikiza iza-bren ndi serplulimab adanenanso za kupulumuka komwe sikunachitikepo. Deta ikuwonetsa chiwopsezo cha kupulumuka kwa chaka chimodzi chomwe chikuyandikira 86%, chiwerengero chomwe chimaposa kwambiri zizindikiro zakale zamatenda akulu. Makinawa akuwoneka kuti samangopha maselo mwachindunji komanso kutembenuka kwa zotupa "zozizira" (zopanda mphamvu) kukhala zotupa "zotentha", potero kumathandizira kuti chitetezo chamthupi chikhale chothandiza.

Zotsatira za synergistic izi zikuwonetsa zomwe zidachitika mu 2026: kupita ku njira zochiritsira zophatikiza. Pogwiritsa ntchito ADC yomwe imayambitsa imfa ya immunogenic cell ndi checkpoint inhibitor yomwe imatulutsa mabuleki pa chitetezo cha mthupi, madokotala akupeza mayankho ozama komanso okhalitsa. Zatsopanozi zikukulitsa chiwongolero cha zotheka njira zazing'ono zothandizira khansa ya m'mapapo.

Kutsata DLL3: Nyengo Yatsopano ya Precision Medicine

Delta-like ligand 3 (DLL3) ndi puloteni yapamtunda yomwe imapezeka m'maselo ang'onoang'ono a khansa ya m'mapapo koma imakhala kulibe m'magulu akuluakulu. Izi zimapangitsa kukhala chandamale chamankhwala olondola. Kwa zaka zambiri, kulunjika ku DLL3 kunali kovuta, koma 2026 yawona kusasitsa kwa njira ziwiri zosiyana: Bispecific T-cell Engagers (BiTEs) ndi Radioligand Therapies.

Tarlatamab: Bispecific T-cell Engager

Tarlatamab ndi bispecific T-cell ochita nawo ma cell omwe amalumikiza ma T-cell a wodwala ndi ma cell a khansa a DLL3. Pothetsa kusiyana kumeneku, kukakamiza chitetezo chamthupi kuukira chotupacho mosasamala kanthu kuti ma T-cell angazindikire khansa.

Kuvomerezeka kofulumira komanso mapulogalamu owonjezera ofikira apangitsa kuti tarlatamab ipezeke kwa odwala omwe abwerera m'mbuyo kapena okana SCLC. Mayesero azachipatala awonetsa ziwopsezo zoyankhira pakati pa 40% ndi 55% mwa anthu omwe adalandira chithandizo kwambiri, chiwerengero cha anthu omwe amawona kuyankha kochepera 10% ndi mankhwala ochiritsira wamba.

Komabe, kugwiritsa ntchito tarlatamab kumafuna kuyang'anira mosamala. Kuyambitsa kwamphamvu kwa T-maselo kumatha kubweretsa Cytokine Release Syndrome (CRS), kuyankha kotupa kwadongosolo. Kuonjezera apo, deta yeniyeni yawonetsa kuopsa kwa chibayo ndi nephritis. Madokotala tsopano amagwiritsa ntchito njira zowongolerera ndikuwunika mozama kuti achepetse zoopsazi, kuwonetsetsa kuti phindu lalikulu la mankhwalawa litha kuzindikirika bwino.

Radioligand Therapy Targeting DLL3

Kupitilira pakuchita nawo ma cell, DLL3 ikuyang'aniridwanso ndi chithandizo cha radioligand. Njira imeneyi imaphatikizapo kulumikiza isotopu ya radioactive ku antibody kapena peptide yomwe imamangiriza ku DLL3. Ma radiation amaperekedwa mwachindunji kumalo otupa, ndikuteteza ziwalo zathanzi zozungulira.

Mayesero oyambirira amasonyeza kuti njirayi ikhoza kukhala yothandiza kwambiri kwa odwala omwe ali ndi matenda ofala kwambiri a metastatic, kuphatikizapo omwe ali ndi mafupa ndi ubongo. Kutha kupereka mlingo waukulu wa ma radiation mwadongosolo popanda kuwopsa kwa ma radiation akunja ndi mwayi wofunikira. Ngakhale akadali ofufuza mu 2026, izi zikuyimira zam'tsogolo Njira yaying'ono yothandizira khansa ya m'mapapo zomwe posachedwapa zitha kulowa muzochita zodziwika bwino.

Kuyerekeza Kuyerekeza kwa Machiritso Oyamba

Ndi kuchuluka kwa mankhwala atsopano, kusankha njira yoyenera kungakhale kovuta. Gome lotsatirali likufananiza fungulo lomwe likutuluka njira zazing'ono zothandizira khansa ya m'mapapo adakambidwa, ndikuwunikira njira zawo, momwe alili pano, komanso momwe angagwiritsire ntchito bwino.

Kuyerekeza uku kumatsimikizira kusiyanasiyana kwa malo a chithandizo. Kumene kunali njira imodzi, tsopano pali njira zingapo zogwirizana ndi magawo osiyanasiyana a matenda ndi mawonekedwe achilengedwe. Kusankhidwa kwa chithandizo kumatengera mankhwala am'mbuyomu, momwe amagwirira ntchito, komanso mbiri ya biomarker.

Kuwongolera Zotsatira Zake ndi Mbiri Zachitetezo

Monga njira zazing'ono zothandizira khansa ya m'mapapo kukhala amphamvu, kuyang'anira zotsatira zake kumakhala kofunika mofanana. Gulu lirilonse la mankhwala limapereka mbiri yake ya kawopsedwe yomwe imafunikira kuwongolera mwachangu.

Zochitika Zoyipa Zokhudzana ndi Immunotherapy (IRAEs)

Immune checkpoint inhibitors imatha kuyambitsa kutupa m'chiwalo chilichonse. IrAEs wamba monga dermatitis, colitis, chiwindi, ndi endocrinopathies monga chithokomiro kukanika. Chochititsa chidwi n'chakuti deta ina imasonyeza kuti odwala omwe ali ndi ma IrAE ochepa amatha kukhala ndi mayankho abwino a chotupa, zomwe zimasonyeza kuti chitetezo cha mthupi chimagwira ntchito.

Kuwongolera nthawi zambiri kumaphatikizapo corticosteroids ndi kuyimitsidwa kwakanthawi kwa mankhwalawa. Kuzindikira msanga ndikofunikira. Odwala amaphunzitsidwa kuti afotokoze zizindikiro monga chifuwa chosalekeza, kutsegula m'mimba, kapena kutopa nthawi yomweyo. Ndi kuyang'anitsitsa koyenera, ma IrAE ambiri ndi osinthika komanso otheka.

ADC-Specific Toxicities

Ma ADC amabweretsa zovuta zawo. Interstitial Lung Disease (ILD) kapena pneumonitis ndi chiopsezo chodziwika ndi malipiro ena, makamaka othandizira a deruxtecan. Kujambula nthawi zonse ndi kuyezetsa ntchito ya m'mapapo kumalamulidwa panthawi ya chithandizo. Kuonjezera apo, poizoni wamagazi monga neutropenia ndi thrombocytopenia ndizofala chifukwa cha chikhalidwe cha cytotoxic cha kuchuluka kwa malipiro.

Mseru, kutopa, ndi alopecia zimakhalanso pafupipafupi koma zimatha kuthetsedwa ndi chithandizo chothandizira. Zenera lazachipatala la ma ADC ndi lopapatiza, lomwe limafunikira dosing yolondola komanso kuyang'anitsitsa ndi gulu lachipatala.

Tarlatamab ndi CRS Management

Kugwiritsa ntchito tarlatamab kumafunikira ma protocol apadera kuti athe kuthana ndi Cytokine Release Syndrome. Zizindikiro zimayambira kutentha pang'ono mpaka kutsika kwamphamvu kwamphamvu kwamphamvu komanso kusagwira bwino ntchito kwa chiwalo. Kuyeza kwapang'onopang'ono, komwe milingo yoyambirira imakhala yocheperako pang'onopang'ono kuti chitetezo cham'thupi chiwonjezeke, chatsimikizika pochepetsa kuopsa kwa CRS.

Kuphatikiza apo, chiopsezo cha chibayo ndi nephritis chomwe chimazindikiridwa pakuwunika kwenikweni chimafuna kuti asing'anga aziwunika momwe kupuma ndi aimpso zimagwirira ntchito. Ngakhale zili zowopsa izi, kuthekera kwa kukhululukidwa kwanthawi yayitali pamilandu yotsutsa kumapangitsa kuti mankhwalawa akhale ofunikira pazida za oncologist.

Njira Zothandiza kwa Odwala ndi Osamalira

Kuyenda mdziko lovuta la chithandizo cha SCLC kungakhale kolemetsa. Pano pali chitsogozo chothandizira odwala ndi mabanja kuti azigwira bwino ntchito ndi othandizira awo azaumoyo njira zazing'ono zothandizira khansa ya m'mapapo.

• Gawo 1: Tsimikizirani Magawo ndi Subtype: Onetsetsani kuti masitepe olondola (Limited vs. Extensive) amakhazikitsidwa pogwiritsa ntchito kujambula kokwanira (CT, MRI, PET). Funsani za ma subtyping a mamolekyulu ngati alipo, chifukwa atha kukhudza kuyenerera kuyesedwa kwachipatala.
• Gawo 2: Kambiranani Njira Yoyambira: Pamatenda anthawi yayitali, tsimikizirani kuti dongosololi limaphatikizapo chemotherapy komanso chitetezo chamthupi. Pazigawo zochepa, funsani za nthawi ya consolidation immunotherapy pambuyo pa chemoradiation.
• Khwerero 3: Yang'anani Mayesero Achipatala: Poganizira za kusinthika kwachangu kwa ntchitoyi, funsani makamaka za mayesero okhudza ma ADC kapena ma DLL3 omwe akuwongolera. Thandizo lopambana limapezeka kokha kudzera mu mapulogalamuwa.
• Gawo 4: Konzani Kuwunika: Khazikitsani ndondomeko ya masikelo nthawi zonse ndi ntchito ya magazi. Mvetsetsani zizindikiro za zotsatira zoyipa monga chibayo kapena CRS ndikudziwa nthawi yoyenera kupeza chithandizo chadzidzidzi.
• Gawo 5: Ganizirani Chisamaliro Chothandizira: Phatikizani chithandizo chamankhwala msanga. Izi sizikutanthauza kusiya; m'malo mwake, imayang'ana kwambiri kasamalidwe ka zizindikiro ndi moyo wabwino, womwe ungathe kuwonjezera kupulumuka pamene ukuphatikizidwa ndi chithandizo chogwira ntchito.

Kukhala woyimira mwanzeru ndikofunikira. Malo a njira zazing'ono zothandizira khansa ya m'mapapo zikusintha mwachangu kuposa kale, ndipo kutenga nawo mbali mwachangu popanga zisankho kungayambitse zotsatira zabwino.

Mayendedwe amtsogolo ndi Horizons Kafukufuku

Kuthamanga kwa kafukufuku wa SCLC sikuwonetsa zizindikiro za kuchepa. Kupatula machiritso omwe akukula mochedwa, njira zingapo zodalirika zikufufuzidwa. Gawo limodzi lochititsa chidwi kwambiri ndi kuphatikiza kwa ma immunomodulators angapo, monga kulumikiza DLL3-targeted BiTE ndi ADC, kapena kuphatikiza ma immunomodulators atatu osiyanasiyana.

Malire ena ndi kugwiritsa ntchito luntha lochita kupanga kulosera kuyankha kwamankhwala. Mwa kusanthula zambiri zamtundu wa genomic ndi zachipatala, mitundu ya AI posachedwapa ikhoza kulangiza zoyenera kuchita bwino. njira zazing'ono zothandizira khansa ya m'mapapo kwa odwala pawokha omwe ali olondola kwambiri.

Kuphatikiza apo, lingaliro la "machiritso ogwira ntchito" likukulirakulira. Ndi omwe apulumuka kwa nthawi yayitali akuchulukirachulukira chifukwa cha immunotherapy ndi othandizira omwe akutukuka kumene, cholinga chake ndikuchoka pakukula kwa moyo kupita kukupeza chikhululukiro chokhalitsa, chopanda chithandizo. Kafukufuku wokhudzana ndi njira zosamalira komanso njira zochepetsera kuwonjezereka kwa oyankha nthawi yayitali akuchitika.

Makatemera olunjika ku ma antigen enieni a SCLC nawonso ali mukukula koyambirira. Makatemera achirewawa amafuna kuphunzitsa chitetezo chamthupi kuti chizindikire ndikuwononga maselo a khansa mwachangu, zomwe zingathe kupewa kuyambiranso pambuyo pochita bwino chithandizo choyambirira.

Kutsiliza: Kuyamba Kwatsopano kwa SCLC Care

Chaka cha 2026 chikuyima ngati mphindi yamadzi m'mbiri ya khansa yaing'ono ya m'mapapo. Kusintha kuchokera ku kaonedwe ka zinthu kopanda chiyembekezo kupita ku chiyembekezo chenicheni kumayendetsedwa ndi kukhwima kwa sayansi ndi kulingalira kwatsopano. Kuphatikizidwa kwa immunotherapy mu muyezo wa chisamaliro chinali chiyambi chabe. Masiku ano, kubwera kwa ma antibody-drug conjugates ngati ifinatamab deruxtecan ndi iza-bren, pamodzi ndi kulondola kwamankhwala omwe amatsata DLL3 monga tarlatamab, kumapereka mwayi womwe sunachitikepo.

Odwala omwe ali ndi SCLC masiku ano ali ndi mwayi wopeza zambiri, zapamwamba kwambiri njira zazing'ono zothandizira khansa ya m'mapapo kuposa kale. Ngakhale zovuta zidakalipo, makamaka pakuwongolera kawopsedwe komanso kuthana ndi kukana, njirayo ndiyokwera kwambiri. Mgwirizano wapakati pa ofufuza, asing'anga, ndi odwala ukuyendetsa kusintha komwe kukupangitsa kuti matenda omwe amapha kamodzi akhale otheka, komanso ochiritsika, nthawi zina.

Pamene tikuyang'ana zam'tsogolo, chidwi chimakhalabe pakupanga munthu payekha komanso kulondola. Kupezeka kwatsopano kulikonse kumatifikitsa kufupi ndi cholinga chachikulu: kuthetsa khansa yaing'ono ya m'mapapo. Pakalipano, uthengawu ndi womveka bwino, pali chiyembekezo, pali zosankha, ndipo nkhondoyo ili kutali.